Cargando…
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
AIMS: In heart failure with reduced ejection fraction (HFrEF), there is an ‘obesity paradox’, where survival is better in patients with a higher body mass index (BMI) and weight loss is associated with worse outcomes. We examined the effect of a sodium–glucose co‐transporter 2 inhibitor according to...
Autores principales: | Adamson, Carly, Jhund, Pardeep S., Docherty, Kieran F., Bělohlávek, Jan, Chiang, Chern‐En, Diez, Mirta, Drożdż, Jarosław, Dukát, Andrej, Howlett, Jonathan, Ljungman, Charlotta E.A., Petrie, Mark C., Schou, Morten, Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Solomon, Scott D., Bengtsson, Olof, Langkilde, Anna Maria, Lindholm, Daniel, Sjöstrand, Mikaela, McMurray, John J.V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292627/ https://www.ncbi.nlm.nih.gov/pubmed/34272791 http://dx.doi.org/10.1002/ejhf.2308 |
Ejemplares similares
-
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021) -
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
por: Curtain, James P, et al.
Publicado: (2021) -
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021) -
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
por: Docherty, Kieran F, et al.
Publicado: (2020) -
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
por: Serenelli, Matteo, et al.
Publicado: (2020)